Morphic Medical Announces CE Mark for RESET® Endoscopic Device Therapy

Morphic Medical Massachusetts

is the developer of RESET, an endoscopically delivered therapy which offers a non-surgical, alternative treatment for morbid obesity and/or obesity in the presence of concurrent cardiometabolic risk factor, e.g., type 2 diabetes and/or dyslipidemia. RESET is not approved for sale in the United States and is limited by federal law to investigational use only. Founded in 2003, Morphic Medical is headquartered in Boston, Massachusetts. For more information, please visit morphicmedical.com or follow us on Twitter and LinkedIn.

Morphic Medical Media Contact:
Investor Relations
[e-mail]
[phone]

Logo - https://mma.prnewswire.com/media/2724347/Morphic_RGB_Logo.jpg 

View original content:https://www.prnewswire.co.uk/news-releases/morphic-medical-announces-ce-mark-for-reset-endoscopic-device-therapy-302498015.html